Stanley H. Hsia - Concepedia

Author

Stanley H. Hsia

Charles R. Drew University of Medicine and Science ORCID

Also Known As

Juan Pablo Frias, Kari Jaasko, S H Hsia, S. H. Hsia, S. Hsia, S.H. Hsia, STANLEY H. HSIA, STANLEY HSIA, Stanley H Hsia, Stanley H. Hsia

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Charles R. Drew University of Medicine and Science Eli Lilly (United States)National Research Institute Velocity Clinical Research (United States)Novartis (United States)

About

Stanley H. Hsia is an author at Charles R. Drew University of Medicine and Science specializing in medicine, metabolic syndrome, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.6K
2	Diabetes	7	7	1.4K
3	Public Health	4	4	154
4	Health Sciences	2	2	70
5	Endocrinology	1	1	18

Stanley H. Hsia

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, The Lancet ObesityMetabolic SyndromeDiabetes ManagementInsulin ManagementDiabetes	2023	590
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Stefano Del Prato, Steven E. Kahn, Imre Pávó, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseMedicineInsulin Management	2021	586
The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men Atam B. Singh, Stanley H. Hsia, Petar Alaupovic, The Journal of Clinical Endocrinology & Metabolism	2002	220
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial Arun J. Sanyal, Patricia López, Eric Lawitz, Nature Medicine	2023	146
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study Juan P. Frías, Stanley H. Hsia, Sarah Eyde, The Lancet Diabetes ManagementMedicineDiabetesClinical TrialsType 2	2023	135
A Population-Based, Cross-Sectional Comparison of Lipid-Related Indexes for Symptoms of Atherosclerotic Disease Stanley H. Hsia, Deyu Pan, P. Berookim, The American Journal of Cardiology ObesityMetabolic SyndromeCross-sectional ComparisonBody CompositionCardiovascular Disease	2006	72
Successful Outcome in Severe Pregnancy-Associated Hyperlipemia: A Case Report and Literature Review Stanley H. Hsia, Philip W. Connelly, Robert A. Hegele The American Journal of the Medical Sciences InfertilityMaternal Cardiovascular OutcomeGestational HypertensionMaternal ComplicationReproductive Health	1995	50
Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results Kathryn Jean Lucas, Patricia López, Eric Lawitz, Digestive and Liver Disease Metabolic SyndromeHepatologyLiver PhysiologyFibrotic NashPharmacology	2020	49
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Julio Rosenstock, Stanley H. Hsia, Luis Nevárez Ruiz, New England Journal of Medicine	2025	46
A Racial Comparison of Differences between Self-Reported and Objectively Measured Physical Activity among US Adults with Diabetes Shahrzad Bazargan‐Hejazi, Jeffrey S. Arroyo, Stanley H. Hsia, Ethnicity & Disease	2017	36

Page 1